ClinicalTrials.gg
Not yet recruitingNCT07948200EPIREUpdated Nov 19, 2026

Urinary DNA Methylation Testing (Bladder EpiCheck®) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer

An interventional study of Bladder EpiCheck in Non-Muscle-Invasive Bladder Cancer, sponsored by Istituto Oncologico Veneto IRCCS. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Istituto Oncologico Veneto IRCCS · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy — 12 open to participants now, 15 under way, 5 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · Italy.

Planned enrollment
21st of 27
60 · median 190
Started
2027
the only one that year
No phase
7 of 30
3 open now
Primary completion
2029-01
later than 11 of 14 live
Registered
30th of 30
by date
Lead sponsor
2 of 30
Istituto Oncologico Veneto IRCCS

Among the 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy, this one is the 21st largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2027, is one of 7 with no phase, reaches primary completion later than 11 of the 14 other live ones, and was the 30th registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

12 of the 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

European Association of Urology (EAU) guidelines mandate a second transurethral resection of bladder tumour (re-TURBt) for patients with high-grade or pT1 non-muscle-invasive bladder cancer (NMIBC) to eradicate residual disease and avoid understaging. However, 30% to 50% or more of patients undergoing re-TURBt have no residual tumour found upon re-resection, incurring surgical and anaesthetic risks, potential morbidity, healthcare costs, and delays in adjuvant therapy without direct oncological benefit.

Current non-invasive triage tools, such as urine cytology and office cystoscopy, suffer from low sensitivity or diagnostic ambiguity due to ongoing post-operative inflammation and tissue healing in a recently resected bladder. While novel molecular biomarkers like Bladder EpiCheck® demonstrate high sensitivity and negative predictive value in the surveillance setting, single-timepoint measurements shortly after resection struggle to differentiate transient, healing-induced epigenetic changes from true persistent malignancy.

Evaluating the longitudinal trajectory of the EpiScore across two distinct post-operative timepoints (T1 and T2) provides a physiological basis for distinguishing decaying inflammatory/reparative signals from stable or rising signals indicative of residual disease. Demonstrating the diagnostic accuracy of Bladder EpiCheck® at T2, alongside the dynamic change in EpiScore (\ΔEpiScore), will establish whether non-invasive urine biomarker testing can reliably select low-risk pT1 NMIBC patients in whom re-TURBt can be safely omitted.

03

Conditions studied

  • Non-Muscle-Invasive Bladder Cancer

Keywords

  • non-muscle-invasive bladder cancer
  • Transurethral resection of bladder tumour
  • Bladder EpiCheck
  • in vitro diagnostic device
  • IVD
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥18 years;
  • confirmed pT1 urothelial carcinoma of the bladder (any grade, WHO 2022 and 1973 classifications) on the definitive histology of the initial TURBt;
  • macroscopically complete initial resection as reported by the surgeon, with detrusor muscle present in the specimen, both formally documented in the operative and pathology records;
  • indication for second TURBt according to EAU guidelines, with the procedure scheduled at the study centre and expected within ten weeks of the initial TURBt;
  • clinically localised non- disease (cN0, cM0);
  • patients able to provide written .
  • Previous BCG treatment is allowed.

Exclusion criteria

Exclusion Criteria:

  • muscle-invasive disease (≥pT2) on the definitive histology of the initial TURBt;
  • initial resection judged incomplete by the operating surgeon - whether because visible tumour was deliberately left behind or because the procedure had to be curtailed and a planned second look arranged - or absence of detrusor muscle in the specimen - these patients receive second TURBt per guidelines but are outside the study question, which concerns the completely resected patient;
  • pure non-urothelial histology (primary adenocarcinoma, pure squamous cell carcinoma, small cell neuroendocrine carcinoma, sarcoma). Variant histologies of urothelial carcinoma are not an exclusion criterion but are recorded as a covariate;
  • concomitant upper tract urothelial carcinoma, or a history of it within the preceding 24 months, given the documented positivity of Bladder EpiCheck® in that disease [19];
  • A single early post-operative chemotherapy instillation, where given, is not an exclusion criterion but is recorded as a covariate;
  • previous pelvic radiotherapy;
  • indwelling urinary catheter or intermittent self-catheterisation; urinary diversion or neobladder;
  • clinically non-localised disease (cN+, cM+);
  • pregnancy or breastfeeding;
  • TURBt performed in an emergency setting for uncontrolled bleeding or other life-threatening indication, in which resection quality cannot be assured;
  • second TURBt not performed at the study centre, with consequent unavailability of the reference standard;
  • patients unable to provide written , or any condition that in the investigator's judgement compromises the ability to comply with study procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    EPIRE

    Device: Bladder EpiCheck

Interventions

  • DeviceBladder EpiCheck

    The investigational IVD medical device evaluated as the index test is the Bladder EpiCheck® system (manufactured by Nucleix Ltd.; exclusive Italian distributor: A. Menarini Diagnostics s.r.l.). The assay is CE-IVD marked under Directive 98/79/EC (Annex III, General IVD category) and cleared by the US FDA via the 510(k) pathway. The manufacturer operates under a certified UNI CEI EN ISO 13485:2016 quality management system. Bladder EpiCheck® profiles the DNA methylation patterns of 15 proprietary DNA biomarkers on genomic DNA isolated from the cellular pellet of a voided urine sample. The assay protocol involves DNA extraction, digestion with a methylation-sensitive restriction enzyme, and subsequent multiplex real-time polymerase chain reaction (multiplex real-time PCR). Dedicated analysis software generates a quantitative integrative score termed the EpiScore, on a continuous scale from 0 to 100. In accordance with the manufacturer's Instructions for Use (IFU), the qualitative diagno

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of Bladder EpiCheck® test at timepoint T2 for residual disease at second TURBt in T1 NMIBC patients.

    Diagnostic accuracy of EpiScore at T2 (categorized as \> 60 positive vs ≤ 60 negative) evaluated against central histopathology review of the second TURBt, measured as Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), Accuracy, and Likelihood Ratios.

    Time frame: Through study completion, an average of 2 years

  2. Diagnostic accuracy of change EpiScore between the two subsequent timepoints T1 and T2.

    Average daily rate of change in EpiScore, calculated as ∆EpiScore=(T2-T1)/(Days between T1 and T2) evaluated against second TURBt residual disease status using a univariate logistic regression model and Area Under the ROC Curve (AUC) with 95% CI.

    Time frame: Through study completion, an average of 2 years

Secondary outcomes

  1. Diagnostic accuracy of Bladder EpiCheck® test at timepoint T1

    Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of EpiScore at T1 (\> 60 vs ≤ 60) for residual disease at second TURBt

    Time frame: Through study completion, an average of 2 years

  2. Diagnostic accuracy of urinary cytology at timepoints T1 and T2

    Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of urinary cytology (Paris System classification) at T1 and T2 against second TURBt histopathology

    Time frame: Through study completion, an average of 2 years

  3. Agreement at T1 and T2 between Bladder EpiCheck® and urinary cytology

    Concordance between Bladder EpiCheck® and urinary cytology at T1 and T2, quantified by Cohen's kappa (κ) coefficient.

    Time frame: Through study completion, an average of 2 years

  4. Agreement between T1 and T2 of Bladder EpiCheck®;

    Agreement on paired aliquots of Bladder EpiCheck® between timepoints T1 and T2 with McNemar's test for paired data

    Time frame: Through study completion, an average of 2 years

  5. Agreement between T1 and T2 of urinary cytology

    Agreement on paired aliquots of urinary cytology between timepoints T1 and T2 with McNemar's test for paired data

    Time frame: Through study completion, an average of 2 years

  6. Diagnostic accuracy at T1 and T2 of the combination of Bladder EpiCheck® and urinary cytology, defined in two versions: (1) as negative when both are negative, (2) as negative when at least one is negative

    Sensitivity, Specificity, PPV, NPV, and Accuracy at T1 and T2 evaluated under two combination definitions: (1) negative when both tests are negative; (2) negative when at least one test is negative

    Time frame: Through study completion, an average of 2 years

  7. Diagnostic accuracy in the previous settings for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt;

    Diagnostic accuracy measures (Sensitivity, Specificity, PPV, NPV) of tests and combinations specifically for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt

    Time frame: Through study completion, an average of 2 years

  8. Diagnostic accuracy of alternative definitions of change in EpiScore

    Diagnostic accuracy and AUC for alternative definitions of Episcore change between T1 and T2: absolute difference (T2-T1) and relative percentage change (T2-T1)/T1;

    Time frame: Through study completion, an average of 2 years

  9. Change in positivity rate of Bladder EpiCheck® and urinary cytology between T1 and T2 among patients whose second TURBt is negative.

    9\) Proportion of test positivity change between T1 and T2 in patients without residual disease (measuring the clearance rate of post-operative false positives).

    Time frame: Through study completion, an average of 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Jan 31, 2027
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948200
Lead sponsor
Istituto Oncologico Veneto IRCCS
Collaborators
Menarini Diagnostics s.r.l
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Jan 31, 2027 (estimated)
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Antonio Amodeo, MD
Contact
antonio.amodeo@iov.veneto.it
0423421321
Gian Luca De Salvo, MD
Contact
clinical.trial@iov.veneto.it
0498215704

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion